CHCWM – Cancer & Hematology Centers of West Michigan

C4731001 ( Pfizer)

Description:  A Phase 1, Open-Label, Dose Escalation and Expansion Study of PF-07265028 as a Single Agent and in Combination with Sasanlimab Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07265028 in Participants with Advanced or Metastatic Solid Tumors

Mechanism of Action:  HPK1 Inhibitor (blocks a novel critical negative regulator in the activation of T lymphocytes and dendritic cells)

Target Patient Population:   Solid tumors

Study Design:  Drug is given orally daily.  Part 1A will be monotherapy and Part 1B will be in combination with Sasanlimab